Molecular Therapy-Oncolytics

Papers
(The TQCC of Molecular Therapy-Oncolytics is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-07-01 to 2026-07-01.)
ArticleCitations
Ferroptosis gene signature in cholangiocarcinoma80
Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence56
Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 153
esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation47
Metabolic remodeling in tumor-associated macrophages contributing to antitumor activity of cryptotanshinone by regulating TRAF6-ASK1 axis44
Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML40
Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma37
A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers36
PROTACs in gastrointestinal cancers35
Cancer stem/progenitor signatures refine the classification of clear cell renal cell carcinoma with stratified prognosis and decreased immunotherapy efficacy35
Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity35
CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer34
Replication-incompetent influenza A viruses armed with IFN-γ effectively mediate immune modulation and tumor destruction in mice harboring lung cancer32
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy31
Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T30
In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiforme30
A library of cancer testis specific T cell receptors for T cell receptor gene therapy28
Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia28
Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia27
The role and application of vesicles in triple-negative breast cancer: Opportunities and challenges26
Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products25
Radiovirotherapy at twenty25
Adding recombinant AAVs to the cancer therapeutics mix25
Oncolytic adenovirus for treatment of malignant ascites24
Bacterial cancer therapy using the attenuated fowl-adapted Salmonella enterica serovar Gallinarum24
Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice23
ScRNA-seq and bulk RNA-seq reveal the characteristics of ferroptosis and establish a risk signature in cholangiocarcinoma23
Seneca Valley virus replicons are packaged in trans and have the capacity to overcome the limitations of viral transgene expression22
The quest for effective immunotherapies against malignant peripheral nerve sheath tumors: Is there hope?22
Mechanisms of drug resistance in breast cancer liver metastases: Dilemmas and opportunities21
Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells21
Thank you to our 2023 reviewers21
Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis21
DNA-damaging cancer cells to improve virotherapy21
Non-coding RNAs and glioma: Focus on cancer stem cells20
Sodium iodide symporter-targeted gene therapy in glioblastoma20
Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers20
An epitope encoded by uORF of RNF10 elicits a therapeutic anti-tumor immune response20
Exploring the potential of eRNAs in cancer immunotherapy19
Optimized NGFR-derived hinges for rapid and efficient enrichment and detection of CAR T cells in vitro and in vivo19
Oncolytic virus-driven immune remodeling revealed in mouse medulloblastomas at single cell resolution19
Gaining insights into virotherapy with canine models19
Purple sweet potato delphinidin-3-rutin represses glioma proliferation by inducing miR-20b-5p/Atg7-dependent cytostatic autophagy19
A new strategy for treating colorectal cancer: Regulating the influence of intestinal flora and oncolytic virus on interferon19
Therapeutic potential of gene therapy for gastrointestinal diseases: Advancements and future perspectives19
A cross-reactive pH-dependent EGFR antibody with improved tumor selectivity and penetration obtained by structure-guided engineering19
Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape19
Comprehensive landscape of tRNA-derived fragments in lung cancer19
0.21527504920959